← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Net income increased 75.5% to ($15.3M), while Operating cash flow decreased 29.0% to ($32.8M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue N/AWatch
- Profitability — Net income ($15.3M)Watch
- Cash generation — Free cash flow ($33.0M)Note
- Accounting — No applicable forensic screenNote
- Insiders — 0 buys; 0 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Business
Corvus Pharmaceuticals, Inc.: Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources.
Leadership changes
From Corvus Pharmaceuticals, Inc.'s own filings, the day they're filed.
- Andrew C. Chan · director · appointmenteff. 2026-04-23
- David Moore · director · departureeff. 2025-10-02
- Edith P. Mitchell · director · departure
Latest filings
- 8-K · Company announcement2026-08-06
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-07-22
- 8-K · Company announcement2026-06-12
- 8-K · Company announcement2026-05-14
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Corvus Pharmaceuticals, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.